Free tool
FAERS Monitor: Miudella
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218201 or its brand name (Miudella, Copper). Reports on generic versions are filed under their own applications.
Reports
737
Serious
493
67% of reports
Hospitalization
219
Death reported
40
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue75
- off label use74
- headache64
- nausea64
- pain62
- diarrhoea61
- drug ineffective52
- weight decreased49
- malaise43
- abdominal pain40
- anaemia36
- dizziness36
- dyspnoea36
- constipation32
- urinary tract infection29
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 9 |
| 2011 | 14 |
| 2012 | 13 |
| 2013 | 21 |
| 2014 | 21 |
| 2015 | 32 |
| 2016 | 60 |
| 2017 | 23 |
| 2018 | 45 |
| 2019 | 56 |
| 2020 | 52 |
| 2021 | 63 |
| 2022 | 69 |
| 2023 | 62 |
| 2024 | 63 |
| 2025 | 67 |
| 2026 | 48 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,422 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaemiaSignal | 36 | 5.4 | 3.9 | 125 |
| weight decreasedSignal | 49 | 5.0 | 3.8 | 155 |
| abdominal painSignal | 40 | 4.9 | 3.6 | 122 |
| urinary tract infectionSignal | 29 | 4.9 | 3.4 | 86 |
| constipationSignal | 32 | 4.2 | 3.0 | 75 |
| headacheSignal | 64 | 2.9 | 2.3 | 81 |
| painSignal | 62 | 2.9 | 2.3 | 76 |
| malaiseSignal | 43 | 2.8 | 2.1 | 49 |
| fatigueSignal | 75 | 2.7 | 2.2 | 85 |
| diarrhoeaSignal | 61 | 2.7 | 2.1 | 65 |
| off label useSignal | 74 | 2.4 | 1.9 | 62 |
| nauseaSignal | 64 | 2.3 | 1.8 | 48 |
| dizzinessSignal | 36 | 2.1 | 1.5 | 19 |
| dyspnoea | 36 | 1.8 | 1.3 | 13 |
| drug ineffective | 52 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.